港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医美概念股

617.971

+4.2550.69%

涨家数：10

跌家数：2

平家数：1

市盈率：- -

高：624.136

开：613.521

低：609.693

收：613.715

数据加载中...

总览新闻资讯

复星医药(02196)：星盛新辉收到国家药监局关于同意XS-03片的药品临床试验批准

人民日报：复星医药推动创新药研发，已上市10余款创新药

复星医药获批XS-03片临床试验

【复星医药：控股子公司XS-03片相关治疗方案获临床试验批准】金融界2月27日消息，复星医药控股子公司江苏星盛新辉医药有限公司的XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验获批准。XS-03是自主研发的小分子口服PLK1抑制剂，在多种肿瘤模型中展现显著药效且临床安全性良好，现阶段针对该方案累计研发投入约20万元。全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。但该方案及XS-03尚需开展系列临床研究并经审批通过方可上市，新药研发存在风险。

三生制药(01530)股价上升5.056%，现价港币$7.48

阿斯达克财经

明起，这条公交线路将调整→

盐酸替那帕诺片在中国获批上市

三生制药盘中异动快速拉升5.06%

时代天使盘中异动快速拉升5.20%报66.750港元

复锐医疗科技盘中异动股价大涨5.08%报4.140港元

复星医药(02196.HK)复方匹可硫酸钠颗粒上市申请获批

阿斯达克财经

复星医药(02196.HK)盐酸替那帕诺片上市申请获批

阿斯达克财经

复星医药(02196.HK)盐酸溴己新注射液药品注册申请获受理

阿斯达克财经

复星医药(02196)：盐酸溴己新注射液的药品注册申请获受理

复星医药(02196)：盐酸替那帕诺片的上市许可申请获国家药监局批准

复星医药：公司对Gland Pharma未来的长期表现充满信心，并将继续推动其在全球市场的发展和增长

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1593/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":617.97076,"timestamp":1741248510330,"preClose":613.71533,"halted":0,"volume":73113617,"delay":0,"changeRate":0.006934,"change":4.255432,"pbRate":1.187551,"amount":463944295,"amplitude":0.023533,"prevYearClose":571.87146,"fiveDayClose":630.978,"twentyDayClose":569.947,"turnoverRate":0.003523,"marketCap":111331486452,"floatMarketCap":73298803508,"peRate":21.508467},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":624.1355,"amplitude":0.023533,"preClose":613.71533,"low":609.69275,"pbRate":"1.187551","latestPrice":617.97076,"volume":73113617,"delay":0,"open":613.5211,"prevYearClose":571.87146,"prevWeekClose":612.07,"prevMonthClose":612.07,"prevQuarterClose":571.871,"fiveDayClose":630.978,"twentyDayClose":569.947,"sixtyDayClose":585.06,"secType":"PLATE","market":"HK","turnoverRate":0.003523,"peRate":21.508467,"marketCap":111331486452,"floatMarketCap":73298803508,"timestamp":1741248510330,"nameCN":"医美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":10,"down":2,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:16,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514492874","title":"复星医药(02196)：星盛新辉收到国家药监局关于同意XS-03片的药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514492874","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514492874?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 18:42","pubTimestamp":1740652968,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，该公司控股子公司江苏星盛新辉医药有限公司于近日收到国家药品监督管理局关于同意XS-03片与FOLFOX或FOLFIRI 和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌临床试验的批准。截至目前的研究显示，XS-03 在多种肿瘤模型中展现较为显著的抑制肿瘤生长的药效，且临床安全性良好。截至本公告日期，XS-03 单药用于治疗RAS突变晚期实体瘤于中国境内处于I期临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0175","BK0183","02196","BK1583","BK0188","600196","BK1576","BK1141","BK1515","BK0196","BK1191","BK0060","BK0096","03347","BK0187","BK0239","BK0012","BK1593"],"gpt_icon":0},{"id":"2514872749","title":"人民日报：复星医药推动创新药研发，已上市10余款创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2514872749","media":"复星","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514872749?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 18:25","pubTimestamp":1740651900,"startTime":"0","endTime":"0","summary":"近年来，中国医药创新领域捷报频传，国产创新药不断涌现。报道中，复星医药作为案例企业之一，展现了复星医药坚持创新驱动，聚焦未满足的临床需求，持续加大研发投入力度，成功推动多款创新药上市，为中国医药产业的高质量发展注入强劲动力。2023年，复星医药研发投入共计59.37亿元，2024年前三季度研发投入39.15亿元。复星医药研发人员超过3400人，其中超1800人拥有硕士及以上学位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-02-27/doc-inemxrkf6344968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","BK0028","BK1191","06978","BK1515","BK0060","BK0175","BK1161","BK0012","BK0187","02196","BK0196","BK0188","BK0183","600196","BK0096","BK0239","BK1593"],"gpt_icon":0},{"id":"2514216820","title":"复星医药获批XS-03片临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2514216820","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514216820?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 17:01","pubTimestamp":1740646881,"startTime":"0","endTime":"0","summary":"2月27日，复星医药发布公告，控股子公司星盛新辉近日获得国家药品监督管理局批准，进行XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验。XS-03为公司自主研发的小分子口服PLK1抑制剂，具有抑制肿瘤细胞增殖及促进肿瘤细胞凋亡的作用。公告指出，全球范围内尚无同靶点的小分子抑制剂获批上市，这为XS-03的临床试验提供了市场机会。2024年前三季度，复星医药实现收入309.12亿元，归母净利润20.11亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271703389894b086&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271703389894b086&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","600196","BK1576","BK1141","BK1583","BK1191","BK1593","02196","03347"],"gpt_icon":0},{"id":"2514891820","title":"【复星医药：控股子公司XS-03片相关治疗方案获临床试验批准】金融界2月27日消息，复星医药控股子公司江苏星盛新辉医药有限公司的XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验获批准。XS-03是自主研发的小分子口服PLK1抑制剂，在多种肿瘤模型中展现显著药效且临床安全性良好，现阶段针对该方案累计研发投入约20万元。全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。但该方案及XS-03尚需开展系列临床研究并经审批通过方可上市，新药研发存在风险。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514891820","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514891820?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 16:54","pubTimestamp":1740646452,"startTime":"0","endTime":"0","summary":"金融界2月27日消息，复星医药控股子公司江苏星盛新辉医药有限公司的XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验获批准。XS-03是自主研发的小分子口服PLK1抑制剂，在多种肿瘤模型中展现显著药效且临床安全性良好，现阶段针对该方案累计研发投入约20万元。全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。但该方案及XS-03尚需开展系列临床研究并经审批通过方可上市，新药研发存在风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27165448428408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1593","BK0196","02196","159938","BK1515","BK1576","BK0028","BK0183","BK1191","BK0012","BK0239","BK1574","600196","BK0096","BK1141","BK0187","BK0175","09939","BK0188","03347","BK1161","BK0060"],"gpt_icon":0},{"id":"2514484005","title":"三生制药(01530)股价上升5.056%，现价港币$7.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2514484005","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514484005?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 14:45","pubTimestamp":1740638700,"startTime":"0","endTime":"0","summary":"[上升股]三生制药(01530) 股价在下午02:45比前收市价上升5.056%，现股价为港币$7.48。至目前为止，今日最高价为$7.65，而最低价为$7.11。总成交量为3.764千万股，总成交金额为港币$2.81亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2502273362/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1593","BK1161","BK1583","01530"],"gpt_icon":0},{"id":"2514846339","title":"明起，这条公交线路将调整→","url":"https://stock-news.laohu8.com/highlight/detail?id=2514846339","media":"媒体滚动","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514846339?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 12:30","pubTimestamp":1740630600,"startTime":"0","endTime":"0","summary":"转自：上观新闻为更好保障吴泾地区居民前往市五医院就医，闵吴线自2025年2月28日起调整走向、站点。下行自吴泾渡口起经贡山路、剑川路、尚义路、永德路、莲花南路、剑川路、沪闵路、鹤庆路、瑞丽路、江川路、沪闵路至闵行止。首末班车时间：闵行5:05—19:50吴泾渡口5:35—20:20供稿：区交通委编辑：陈依婷","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-02-27/doc-inemwynh7111876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1593","BK1209","02135"],"gpt_icon":0},{"id":"2514565812","title":"盐酸替那帕诺片在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2514565812","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514565812?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 10:31","pubTimestamp":1740623469,"startTime":"0","endTime":"0","summary":"新京报讯2月26日，复星医药发布公告，其控股子公司上海复星医药产业发展有限公司（“复星医药产业”）获独家开发和商业化许可的全新机制降磷创新药盐酸替那帕诺片（中国境内商品名：万缇乐）获国家药监局批准上市，用于控制对磷结合剂疗效不充分或不耐受的慢性肾脏病（CKD）成人透析患者的血清磷水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502273331316619.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502273331316619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","BK1593","BK1191","BK1515"],"gpt_icon":0},{"id":"2514819482","title":"三生制药盘中异动 快速拉升5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514819482","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514819482?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 09:41","pubTimestamp":1740620499,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时41分，三生制药股票出现异动，股价急速拉升5.06%。截至发稿，该股报7.480港元/股，成交量604.5万股，换手率0.25%，振幅5.20%。三生制药股票所在的药品行业中，整体跌幅为0.02%。其相关个股中，开拓药业-B、君圣泰医药-B、三生制药涨幅较大，振幅较大的相关个股有开拓药业-B、君圣泰医药-B、德琪医药-B，振幅分别为11.11%、7.83%、5.20%。三生制药公司简介：投资控股,及本集团主要在中国从事开发、生产、营销及销售生物医药产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227094139989433b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227094139989433b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1593","BK1161","01530"],"gpt_icon":0},{"id":"2514816559","title":"时代天使盘中异动 快速拉升5.20%报66.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514816559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514816559?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 09:37","pubTimestamp":1740620276,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时37分，时代天使股票出现波动，股价快速上涨5.20%。截至发稿，该股报66.750港元/股，成交量3.64万股，换手率0.02%，振幅4.33%。资金方面，该股资金流入190.56万港元，流出18.177万港元。时代天使股票所在的医疗及医学美容服务行业中，整体涨幅为0.13%。其相关个股中，时代天使、医渡科技、瑞尔集团涨幅较大，振幅较大的相关个股有艾迪康控股、时代天使、医脉通，振幅分别为5.03%、4.33%、4.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227093756abde83e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227093756abde83e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06699","BK1587","BK1583","BK1100","BK1593"],"gpt_icon":0},{"id":"2514816388","title":"复锐医疗科技盘中异动 股价大涨5.08%报4.140港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514816388","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514816388?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 09:35","pubTimestamp":1740620138,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时35分，复锐医疗科技股票出现异动，股价急速上涨5.08%。截至发稿，该股报4.140港元/股，成交量14.56万股，换手率0.03%，振幅5.08%。资金方面，该股资金流入46.536万港元，流出7.8424万港元。复锐医疗科技股票所在的医疗设备及用品行业中，整体涨幅为0.16%。其相关个股中，百心安-B、复锐医疗科技、先健科技涨幅较大，振幅较大的相关个股有百心安-B、复锐医疗科技、威高股份，振幅分别为37.89%、4.57%、4.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270935389631d4e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270935389631d4e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1100","BK1593","01696"],"gpt_icon":0},{"id":"2514813353","title":"复星医药(02196.HK)复方匹可硫酸钠颗粒上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2514813353","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514813353?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 08:58","pubTimestamp":1740617880,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司苏州二叶制药就复方匹可硫酸钠颗粒的上市注册申请，已于近日获国家药品监督管理局批准。该药品为复星医药自主研发的化学药品，主要用于结肠镜检查、X光检查前的肠道清洁准备，用于必要时在外科手术前清洁肠道。截至2025年1月，集团现阶段针对该药品累计研发投入约为853万元人民币。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131534109_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131534109_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420582/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0012","BK0096","BK1515","600196","BK0196","BK0175","BK1191","BK1593","BK0187","BK0183","BK0239","02196","BK0188","BK0028","BK0060"],"gpt_icon":0},{"id":"2514181803","title":"复星医药(02196.HK)盐酸替那帕诺片上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2514181803","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514181803?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 08:54","pubTimestamp":1740617640,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司上海复星医药产业获许可产品盐酸替那帕诺片(商品名“万缇乐”)，上市许可申请于近日获国家药品监督管理局批准，获批适应症为用于控制对磷结合剂疗效不充分或不耐受的慢性肾脏病(CKD)成人透析患者的血清磷水平。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420580/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0028","BK0060","BK1191","02196","BK0012","BK0175","BK0188","BK0096","BK0187","600196","BK0183","BK0196","BK1515","BK1593","BK0239"],"gpt_icon":0},{"id":"2514856645","title":"复星医药(02196.HK)盐酸溴己新注射液药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856645","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514856645?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 22:42","pubTimestamp":1740580920,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司重庆药友制药就盐酸溴己新注射液的药品注册申请于近日获国家药品监督管理局受理。盐酸溴己新注射液为集团自主研发的化学药品。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420477/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0188","BK0028","BK0096","BK0183","BK0239","600196","BK1515","BK1593","BK0060","BK1191","BK0187","BK0196","BK0012","02196","BK0175"],"gpt_icon":0},{"id":"2514880968","title":"复星医药(02196)：盐酸溴己新注射液的药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2514880968","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514880968?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 18:33","pubTimestamp":1740566027,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司重庆药友制药有限责任公司就盐酸溴己新注射液(以下简称“该药品”)的药品注册申请于近日获国家药品监督管理局受理。盐酸溴己新注射液为集团(即公司及控股子公司/单位，下同)自主研发的化学药品。该药品拟用于在口服给药困难的情况下，以下疾病和症状的祛痰：肺结核、尘肺病、手术后。截至2025年1月，集团现阶段针对盐酸溴己新注射液的累计研发投入约为人民币164万元(未经审计)。根据IQVIACHPA最新数据，2023年，盐酸溴己新注射剂于中国境内(不包括港澳台地区)的销售额约为人民币15.89亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK0187","BK1515","02196","BK0012","BK0183","BK0060","BK0196","BK0028","BK0175","BK1191","BK0096","BK1593","600196"],"gpt_icon":0},{"id":"2514788755","title":"复星医药(02196)：盐酸替那帕诺片的上市许可申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514788755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514788755?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 18:14","pubTimestamp":1740564847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，公司控股子公司上海复星医药产业发展有限公司(简称“复星医药产业”)获许可产品盐酸替那帕诺片(中国内地 商品名：万缇乐® )的上市许可申请于近日获国家药品监督管理局批准，本次获批适应症为用于控制对磷结合剂疗效不充分或不耐受的慢性肾脏病(CKD)成人透析患者的血清磷水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK1191","BK0096","BK0183","BK0239","BK1593","BK0012","BK0187","BK1515","BK0060","600196","02196","BK0175","BK0028","BK0196"],"gpt_icon":0},{"id":"2514588749","title":"复星医药：公司对Gland Pharma未来的长期表现充满信心，并将继续推动其在全球市场的发展和增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2514588749","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514588749?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 18:09","pubTimestamp":1740564544,"startTime":"0","endTime":"0","summary":"有投资者向复星医药提问， 据印度媒体报道，复星医药准备出售印度公司glandpharma的所有股权，作价30亿美元，目前正与黑石集体洽谈，请问上述报道属实吗？谢谢！公司回答表示，投资者您好！Gland Pharma是公司全球化战略中的重要组成部分。截至目前，公司持有Gland Pharma 51.83%的股权。公司对Gland Pharma未来的长期表现充满信心，并将继续推动其在全球市场的发展和增长。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226181519abddac96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226181519abddac96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600196","02196","BK1515","BK1191","BK1593"],"gpt_icon":0}],"pageSize":16,"totalPage":9,"pageCount":5,"totalSize":144}]}}